Centre Hospitalier De Dax
- Address
- lock Available on a paid plan
Immune System Diseases at Centre Hospitalier De Dax
Clinical research in immune system diseases focuses on giant cell arteritis, with studies designed to better understand how to maintain disease control while adjusting treatment. The main goal is to evaluate whether different approaches to stopping therapy can help reduce the risk of relapse.
- Relapse prevention in giant cell arteritis
- Evaluating treatment discontinuation strategies
- Improving long-term disease management
This work supports more personalized care for patients living with inflammatory conditions treated in internal medicine.
Musculoskeletal Research
Studies in musculoskeletal diseases are centered on knee osteoarthritis pain, with the aim of testing whether a new therapy can provide better pain relief than standard care. The research is focused on improving everyday comfort and function for people affected by joint disease.
- Knee osteoarthritis pain relief
- Testing a new treatment for symptom control
- Assessing effectiveness compared with placebo
These trials reflect a practical effort to find better options for managing chronic joint pain at the hospital level.
Respiratory Tract Disease Studies
Research in respiratory tract diseases addresses de novo acute respiratory failure, with a focus on supporting patients who need high-flow oxygen treatment. The purpose of the trial is to improve the process of weaning patients from respiratory support and increase the chances of successful recovery.
- Acute respiratory failure care
- Optimizing weaning from high-flow oxygen therapy
- Improving recovery in intensive care settings
This area highlights clinically important work aimed at making critical care treatment safer and more effective.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 14 therapeutic areas and 15 of 61 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 59 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier De Dax
lock Showing 1 of 24 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multicentre randomized, double-blind, placebo-controlled, dose-finding, Phase 2 study (MARS-17) of GSK3858279 in adult participants with moderate to severe pain due to knee osteoarthritis. | Glaxosmithkline Research & Development Limited | Phase II | Not Recruiting | Nov 2023 | Aug 2024 |
IMP list
lock Showing 1 of 61 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Tocilizumab | 5 | Unknown | 2016-02-19 | 2025-06-06 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.